TY  - JOUR
AU  - Ocana, Alberto
AU  - Gil-Martin, Marta
AU  - Martín, Miguel
AU  - Rojo, Federico
AU  - Antolín, Silvia
AU  - Guerrero, Ángel
AU  - Trigo, José Manuel
AU  - Muñoz, Montse
AU  - Pandiella, Atanasio
AU  - Diego, Núria Gonzalo
AU  - Bezares, Susana
AU  - Caballero, Rosalía
AU  - Carrasco, Eva
AU  - Urruticoechea, Ander
PY  - 2017
DO  - 10.18632/oncotarget.17113
UR  - https://hdl.handle.net/10668/25132
T2  - Oncotarget
AB  - The anti-HER2 antibody trastuzumab have shown clinical activity in combination with chemotherapy in different breast cancer settings. However, most of patients treated with this antibody progress after a period of treatment. Activation of the kinase...
LA  - en
KW  - HER2 positive breast cancer
KW  - SRC kinase
KW  - dasatinib
KW  - metastatic breast cancer
KW  - trastuzumab resistance
TI  - A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
TY  - research article
VL  - 8
ER  -